, Volume 54, Supplement 3, pp 51–58 | Cite as

The Medical Economics of Stroke

  • Thomas N. Taylor


The economic consequences of the approximately 500 000 strokes that occur each year in the US are staggering. The direct cost of providing care for stroke victims in 1993 has been estimated to be $US 17 billion, with an additional $US 13 billion in indirect costs attributable to lost earnings due to stroke-related mortality and morbidity. Estimates of the cost of stroke over a patient’s lifetime vary according to age at first stroke and type of stroke. In 1990, these estimates ranged from $US91 000 for ischaemic stroke, $US124 000 for intracerebral haemorrhage, and $US228 000 for subarachnoid haemorrhage.

Factors driving the economics of stroke include the epidemiology of stroke, treatment patterns and settings, and social and behavioural factors. Evaluating the economic consequences of alternative interventions designed to prevent strokes or improve stroke outcomes involves a weighing of incremental costs and effectiveness. Previous efforts have focused primarily on measuring costs, with a recent shift to trying to measure patient preferences for stroke outcomes.


Ischaemic Stroke Indirect Cost Direct Cost Intracerebral Haemorrhage Lifetime Cost 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the United States. Stroke 1996; 27: 1459–66PubMedCrossRefGoogle Scholar
  2. 2.
    Broderick JP, Phillips EJ, Whisnant JP, et al. Incidence rates of stroke in the eighties: the end of the decline of stroke? Stroke 1989; 20: 577–82PubMedCrossRefGoogle Scholar
  3. 3.
    Matchar DB, Duncan PW. Cost of stroke. Stroke Clin Updates 1994; 5: 9–12Google Scholar
  4. 4.
    Holloway RG, Witter DM, Lawton MA, et al. Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology 1996; 46: 854–60PubMedCrossRefGoogle Scholar
  5. 5.
    Liebson CL, Hu T, Brown RD, et al. Utilization of acute care services in the year prior to and following first stroke: a population-based study. Neurology 1996; 46: 861–9Google Scholar
  6. 6.
    Lee AJ, Huber J, Stason WB. Poststroke rehabilitation in older Americans. The Medicare experience. Med Care 1996: 34: 811–25PubMedCrossRefGoogle Scholar
  7. 7.
    Bergman L, van der Meulen JPH, Limburg M, et al. Costs of medical care after first-ever stroke in The Netherlands. Stroke 1996; 26: 1830–6CrossRefGoogle Scholar
  8. 8.
    Kappelle LJ, Adams Jr HP, Heffner ML, et al. Prognosis of young adults with ischemic stroke. A long-term follow-up study assessing recurrent vascular events and functional outcome in the Iowa Registry of Stroke in Young Adults. Stroke 1994; 25: 1360–5PubMedCrossRefGoogle Scholar
  9. 9.
    Hartunian NS, Smart CN, Thompson MS. The incidence and economic cost of cancer, motor vehicle injuries, coronary heart disease, and stroke. Am J Public Health 1980; 70: 1249–60PubMedCrossRefGoogle Scholar
  10. 10.
    Australian Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including major submissions involving economic analyses. Canberra: Australian Government Publishing Service, 1995Google Scholar
  11. 11.
    Torrance GW, Blaker D, Detsky A, et al. Canadian guidelines for economic evaluation of pharmaceuticals. Pharmaco-Economics 1996; 9: 535CrossRefGoogle Scholar
  12. 12.
    Solomon NA, Glick HA, Russo CJ, et al. Patient preferences for stroke outcomes. Stroke 1994; 25: 1721–5PubMedCrossRefGoogle Scholar
  13. 13.
    Edgar MA, Schnieden H. The economics of mild hypertension programmes. Soc Sci Med 1989; 28: 211–22PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • Thomas N. Taylor
    • 1
  1. 1.Program in Pharmaceutical Outcomes and Policy Research, College of PharmacyUniversity of IowaIowa CityUSA

Personalised recommendations